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Individuals with the neurofibromatosis 1 (NF1) inherited tumor syndrome develop low-grade gliomas
(astrocytomas) at an increased frequency, suggesting that the NF1 gene is a critical growth regulator for
astrocytes. In an effort to determine the contribution of the NF1 gene product, neurofibromin, to astrocyte
growth regulation and NF1-associated astrocytoma formation, we generated astrocyte-specific Nf1 conditional
knockout mice (Nf1GFAPCKO) by using Cre/LoxP technology. Transgenic mice were developed in which Cre
recombinase was specifically expressed in astrocytes by embryonic day 14.5. Successive intercrossing with mice
bearing a conditional Nf1 allele (Nf1flox) resulted in GFAP-Cre Nf1flox/flox (Nf1GFAPCKO) animals. No astro-
cytoma formation or neurological impairment was observed in Nf1GFAPCKO mice after 20 months, but in-
creased numbers of proliferating astrocytes were observed in several brain regions. To determine the conse-
quence of Nf1 inactivation at different developmental times, the growth properties of embryonic day 12.5 and
postnatal day 2 Nf1 null astrocytes were analyzed. Nf1 null astrocytes exhibited increased proliferation but
lacked tumorigenic properties in vitro and did not form tumors when injected into immunocompromised
mouse brains in vivo. Collectively, our results suggest that loss of neurofibromin is not sufficient for astrocy-
toma formation in mice and that other genetic or environmental factors might influence NF1-associated glioma
tumorigenesis.
Neurofibromatosis 1 (NF1) is the most common cancer pre-
disposition syndrome affecting the nervous system, with an
incidence of 1 in 3,500 births worldwide (16). Early in life,
individuals with NF1 develop cafe´-au-lait spots, skinfold freck-
ling, and iris hamartomas (Lisch nodules). In addition, approx-
imately 15 to 20% of children with NF1 develop glial cell
tumors (astrocytomas) involving the optic nerve, chiasm, hy-
pothalamus, and brain stem (31). Although classified as grade
I juvenile pilocytic astrocytomas, these tumors can be associ-
ated with significant morbidity as a result of visual loss or
neurological compromise.
Since individuals affected with NF1 develop tumors at an
increased frequency, the NF1 gene is hypothesized to function
as a tumor suppressor. Identification of the NF1 gene (10, 42,
43) and its protein product, the 220- to 250-kDa cytoplasmic
neurofibromin protein, revealed that a small portion of the
molecule has sequence similarity with the catalytic domain of a
family of proteins termed GTPase-activating proteins (GAPs)
(4, 34, 45). GAP molecules function as negative regulators of
small mitogenic GTPase proteins, like p21ras, and inactivate
these signaling proteins by accelerating their conversion from
active, GTP-bound conformations to inactive, GDP-bound
forms (6). In NF1-associated tumors, loss of neurofibromin
results in increased p21ras mitogenic signaling and augments
cell proliferation, leading to tumor formation (5, 7, 12).
In support of a role for neurofibromin as a negative astrocyte
growth regulator, we have previously demonstrated that neu-
rofibromin expression increases during astrocyte growth arrest
in vitro (18). In addition, neurofibromin expression is absent in
symptomatic NF1-associated pilocytic astrocytomas, consistent
with the notion that homozygous inactivation of the NF1 gene
is associated with astrocytoma formation in NF1 (19). More-
over, in one NF1 patient astrocytoma, loss of neurofibromin
expression was associated with increased levels of activated
p21ras (28). However, it is not known whether loss of neurofi-
bromin is sufficient for astrocytoma formation.
Mice with targeted disruption of the Nf1 gene have been
developed. Mice heterozygous for a mutated Nf1 gene (Nf1/
mice) develop several types of tumors, including pheochromo-
cytomas and lymphoid leukemias (8, 24). Despite the absence
of astrocytomas in these mice, Nf1/ mice exhibit a 1.5-fold
increase in astrocyte proliferation in vivo (18). This heterozy-
gote growth advantage is specific to astrocytes and not seen in
oligodendrocytes or microglia. Moreover, heterozygosity for
another p21ras-GAP molecule, p120-GAP, does not result in
increased astrocyte proliferation in vivo. We further demon-
strated that this growth advantage is cell autonomous, in that
Nf1/ astrocytes proliferate faster in vitro than wild-type lit-
termate astrocytes and exhibit elevated p21ras pathway activa-
tion (3). The lack of astrocytic tumors in Nf1/ mice may
reflect the need for further genetic alterations, such as inacti-
vation of the other Nf1 allele or loss of other tumor suppressor
genes.
Genetic cooperativity between the Nf1 tumor suppressor
and other tumor suppressor genes important in sporadic as-
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trocytoma pathogenesis (p53 and Rb) has been demonstrated.
Heterozygosity for both Nf1 and p53 or Rb confers a significant
growth advantage to brain astrocytes: Nf1/ p53/ mice
exhibit a threefold increase in astrocyte proliferation in vivo,
while Nf1/ Rb/ mice exhibit a 2.5-fold increase in astro-
cyte proliferation in vivo compared to wild-type mice (3). Com-
bined loss of both Nf1 and p53 was shown to result in high-
grade malignant astrocytoma (glioblastoma) formation (39),
different from the benign pilocytic astrocytomas in individuals
with NF1 who do not harbor p53 mutations (23, 30).
Germ line homozygosity for an Nf1 mutation (Nf1/) re-
sults in embryonic lethality between days 12.5 and 14.5 of
gestation, secondary to a cardiac vessel defect (8, 24). Because
these mice die during mid-embryonic development, the effect
of absent neurofibromin expression on normal astrocyte dif-
ferentiation and the development of astrocytomas cannot be
directly addressed. The recent development of Nf1 conditional
mutant mice (Nf1flox/flox mice) by using Cre/LoxP technology
now permits such an analysis (48).
The first tissue-specific Nf1 conditional knockout mouse was
generated by inactivation of the Nf1 gene in differentiated
neurons by using the synapsin I promoter (NF1Syn1KO) (48).
NF1Syn1KO mice exhibited reduced forebrain weight, changes
in neuronal physiology, activation of the p21ras/mitogen-acti-
vated protein kinase pathway in neurons, and massive astro-
gliosis in the cerebral cortex, hippocampus, and brain stem.
The astrocytes in these brain areas were not proliferating and
demonstrated morphological changes suggestive of reactive
astrocytes. Although this mouse model represents an excellent
model to study the learning disabilities associated with NF1,
NF1SynIKO mice were tumor-free and did not develop astro-
cytomas.
The development of a mouse model for NF1-associated as-
trocytomas is an important first step for future translational
research efforts relevant to these common tumors in individu-
als with NF1. In this report, we describe the development of
several astrocyte-specific Cre (GFAP-Cre) transgenic mouse
lines, the generation of astrocyte-specific Nf1 conditional
knockout mice (Nf1GFAPCKO mice), and characterization of
the effects of Nf1 inactivation at different developmental peri-
ods on astrocyte growth and tumor formation. Our results
suggest that Nf1 inactivation alone may not be sufficient for
astrocytoma formation in mice.
MATERIALS AND METHODS
Transgenic mice. GFAP-Cre-IRES-LacZ transgenic mice (GFAP-Cre mice)
were generated by pronuclear injection of the purified, linearized 8-kbp GFAP-
Cre-internal ribosome entry site (IRES)-lacZ DNA fragment into C57BL/6 
CBA fertilized mouse eggs by using standard techniques in the Neuroscience
Transgenic Facility at the Washington University School of Medicine. The trans-
gene construct consists of the 2.2-kb fragment of the human glial fibrillary acidic
protein (GFAP) promoter (Gfa2) (obtained from M. Brenner, National Institute
of Neurological Disorders and Stroke) (9), the encephalomyocarditis virus IRES,
the cDNA encoding the nucleus-targeted Cre recombinase (provided by J. Mil-
brandt, Washington University, St. Louis, Mo.) (26), and the cDNA encoding a
nucleus-targeted LacZ, followed by the simian virus 40 polyadenylation signal
(provided by A. Nagy, Mount Sinai Hospital, Toronto, Canada). The IRES-LacZ
allows for cotranslation of the Cre and LacZ proteins from the same mRNA and
permits indirect detection of the Cre expression pattern in vivo.
Transgenic mice carrying the GFAP-Cre-IRES-LacZ transgene were identi-
fied by tail DNA PCR from 1-week-old mice or from embryonic tail or amniotic
tissue by using Cre- and LacZ-specific primers. Briefly, mouse tails were treated
with 200 l of tail extraction buffer (50 mM Tris-HCl [pH 7.4], 1 mM CaCl2, 1%
Tween 20) plus 25 l of 1% proteinase K at 55°C overnight. Then 1 l of tail
DNA was subjected to PCR amplification with the following primers and con-
ditions: CRE, 5-GTGTCCAATTTACTGACCGTACAC-3 and 5-CTAATCG
CCATCTTCCAGCAG-3, at an annealing temperature of 60°C for 30 cycles;
and LACZ, 5-CCAGCTGGCGTAATAGCGAAG-3 and 5-CATCGTAACC
GTGCATCTGCC-3, at an annealing temperature of 62°C for 38 cycles.
The PCR results were confirmed by Southern blotting. A total of 10 g of tail
genomic DNA, digested with BglII and NotI to excise the GFAP-Cre-IRES-LacZ
transgene, and 0.5 g of the original GFAP-Cre-IRES-LacZ BglII/NotI fragment
used for pronuclear injection were separated by 1% agarose gel electrophoresis,
followed by capillary transfer onto Hybond-N nylon membranes (Amersham,
Piscataway, N.J.). The HindIII Cre fragment (1 kb) of the PSA-Cre-HGH
construct was labeled with [-32P]dATP by using the Prime-a-gene labeling
system (Promega, Madison, Wis.). The 32P-radiolabeled Cre-purified probe was
hybridized to the membranes at 42°C overnight, washed three times in 2 SSC
(1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.1% sodium dodecyl
sulfate (SDS) at 60°C, and exposed at 80°C for 48 h. Three founders were
identified by PCR and Southern blotting and bred with C57BL/6 mice to gen-
erate three transgenic lines (1, 6, and 8).
To establish astrocyte-specific Nf1 knockout mice, each of the three GFAP-
Cre lines was crossed with the Nf1flox/flox mice, containing LoxP sites flanking
exons 31 and 32 of the Nf1 gene. The Nf1flox/flox mice were genotyped, and
recombination PCR was performed with specific primers able to recognize only
the recombined Nf1 gene (48).
Nf1/ mice were generously provided by Neal Copeland (National Institutes
of Health) (8). All mouse strains are maintained as permanent colonies in the
Department of Comparative Medicine small-animal barrier facility at the Wash-
ington University School of Medicine.
Staged embryos for LacZ reporter expression analysis were generated by
breeding GFAP-Cre transgenic mice with C57BL/6 mice, while embryonic E12.5
Nf1/ astrocyte cultures were generated by interbreeding Nf1/ mice, with the
assignment of noon on the day after the appearance of a mucous plug in mated
animals as embryonic day 0.5 (E0.5).
Tissue preparation for histological analysis. For -galactosidase activity
and/or immunohistochemistry of brain sections, mice were perfused transcardi-
ally with 0.1 M sodium phosphate buffer, pH 7.4, followed by 4% paraformal-
dehyde in 0.1 M sodium phosphate buffer, pH 7.4. The brains were removed and
fixed by immersion in 4% paraformaldehyde in 0.1 M phosphate buffer overnight
at 4°C. After fixation, the brains were cryoprotected in 30% sucrose solution in
0.1 M phosphate buffer at 4°C. For microtome sections, the cryopreserved brains
were frozen in powdered dry ice. Tissue sections were then cut in the coronal
plane at 40 m on a freezing sliding MICROM HM 400 microtome (Microme
GmbH, Berlin, Germany).
For -galactosidase activity staining, staged embryos were removed in cold 0.1
M phosphate buffer (pH 7.4) and fixed in 4% paraformaldehyde in 0.1 M
phosphate buffer for 24 h at 4°C. Whole 11.5- and 13.5-day-old embryos and
bisected 14.5-, 15.5-, and 18.5-day-old embryos were rinsed with phosphate-
buffered saline (PBS) buffer (pH 7.3) prior to 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-Gal) staining.
For hematoxylin and eosin staining, GFAP immunohistochemistry, PCNA/
GFAP and LacZ/Cre double immunofluorescence of brain sections, and S-100
staining of sciatic nerve sections, brains and sciatic nerves of the Nf1GFAPCKO as
well as control Nf1flox/flox and Nf1flox/wt mice were removed, washed with PBS,
and fixed overnight in Bouin’s fixative (15 parts saturated picric acid, 5 parts 37%
formaldehyde, 1 part glacial acetic acid; Sigma, St. Louis, Mo.). The brains and
sciatic nerves were washed in 70% ethanol and submitted in 70% ethanol to the
Washington University Molecular Biology and Pharmacology Histology Core
Facility for paraffin embedding and sectioning.
Immunostaining and astrocyte counting. GFAP was employed as a marker for
mature differentiated astrocytes in the brain, while adenomatous polyposis coli
(APC), microtubule-associated protein 2 (MAP2), and S-100 were used as pro-
tein markers for oligodendrocytes, neurons, and Schwann cells, respectively.
Free-floating sections (40 m) were processed for immunohistochemistry by
using a rat monoclonal anti-GFAP antibody (1:10,000 dilution; Zymed, San
Francisco, Calif.), a mouse monoclonal anti-APC antibody (1:500 dilution; On-
cogene, Cambridge, Mass.), and a mouse monoclonal anti-MAP2 antibody (1:
500 dilution; PharMingen, San Diego, Calif.), respectively. Sciatic nerve paraffin
sections (4 m) were processed for S-100 staining with a polyclonal anti-S-100
antibody (1:50,000 dilution; Z311, Dako, Carpinteria, Calif.). Cre immunostain-
ing was performed on 40-m free-floating sections with a polyclonal anti-Cre
antibody (1:60,000 dilution; Novagen, Madison, Wis.).
Brain sections were then incubated with biotinylated secondary antibodies
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(1:1,000 dilution) and detected with the Vectastain ABC Elite kit (Vector Lab-
oratories, Burlingame, Calif.). The substrate for the horseradish peroxidase color
reaction was diaminobenzidine (DAB; brown reaction product). For combined
immunohistochemistry and -galactosidase staining, brain sections from 7- to
14-day-old GFAP-Cre transgenic mice were first processed for GFAP, APC, or
MAP2 immunohistochemistry followed by LacZ histochemistry. -Galactosidase
staining was performed by incubating the brain sections for several hours to
overnight at 37°C in PBS buffer (pH 7.3) containing 2 mM MgCl2, 0.02% NP 40,
0.01% sodium deoxycholate, 5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide, and 1 mg of X-Gal per ml. Sections were mounted on slides with
Cytoseal-60 mounting medium for microscopy (Stephens Scientific, Kalamazoo,
Mich.) and photographed with a digital camera (Optronics) attached to an
inverted microscope (Nikon).
To analyze LacZ expression during embryonic development of GFAP-Cre
transgenic mice, staged embryos were stained as above for brain sections. After
several rinses with PBS (pH 7.3), embryos were photographed with a digital
camera (Optronics) attached to a dissection microscope (Nikon).
GFAP-immunoreactive astrocytes were counted in the CA1 region of the
hippocampus of brain sections from adult and 2-, 6-, and 12-month-old
Nf1GFAPCKO mice and control mice (18, 37). Two-month-old GFAP-Cre and
Nf1flox/flox mice and 6- and 12-month-old Nf1flox/flox and Nf1flox/wt mice were
used as controls. Astrocytes were counted in six consecutive serial sections per
brain obtained from four to six animals of each genotype. Data are presented as
means 	 standard deviations (SD) and were analyzed with analysis of variance
followed by the Bonferoni T test, with significance set at P 
 0.05.
Hematoxylin and eosin staining was performed according to standard proto-
cols.
PCNA/GFAP and Cre/LacZ double immunofluorescence. For tyramide signal
amplification enhanced immunohistochemical detection (46), 4-m paraffin sec-
tions were first subjected to deparaffinization in Citrisolv (Fisher Scientific) and
then incubated overnight at 4°C with primary antibodies: for PCNA, goat poly-
clonal anti-PCNA antibody (C20) (1:800 dilution; Santa Cruz); for GFAP, a rat
monoclonal anti-GFAP antibody (1:100 dilution; Zymed, San Francisco, Calif.);
for Cre, a rabbit polyclonal antibody (1:6,000; Novagen, Madison, Wis.); and for
LacZ, a mouse monoclonal antibody (1:500; Oncogene, Boston, Mass.). Second-
ary horse anti-goat (Vector Laboratories, Burlingame, Calif.; 1:1,000), rabbit
anti-rat (Sigma; 1:1,000), goat anti-mouse (Sigma; 1:1,000), and goat anti-rabbit
(Sigma; 1:2,000) antibodies were used. TSA-Plus fluorescein and cyanin 3 system
kits (Perkin-Elmer Life Sciences, Inc., Boston, Mass.) were used for fluorescence
detection by following the manufacturer’s directions. Sections were mounted in
Vectashield mounting medium for fluorescence with DAPI (4,6-diamidino-2-
phenylindole) (Vector Laboratories, Burlingame, Calif.). DAPI was used to
counterstain DNA and identify cell nuclei in the sections.
Primary astrocyte cultures. Murine neocortical astrocyte cultures were estab-
lished from postnatal day 2 pups as previously described (3, 21). E12.5 astrocyte
cultures were generated from the forebrains of 12.5-day-old embryos removed
from euthanized Nf1/ timed-pregnancy mothers. Genotypes were determined
by PCR from tail DNA.
Astrocyte proliferation in culture was determined by direct counting or thy-
midine incorporation. For direct counting, 105 cells were seeded, harvested after
3 and 6 days in culture (1, 3, and 5 days), and counted by using a Hausser
Scientific hemacytometer. [3H]thymidine incorporation was performed as previ-
ously reported (18).
Cell cycle analysis of cultured astrocytes was performed by measuring the
cellular DNA content by flow cytometry, according to established protocols (36).
Briefly, 105 cells were seeded in 100-mm culture dishes maintained in growth
medium with 10% horse serum and harvested at 75% confluency for flow cy-
tometry of the DNA content. The cells were washed with PBS and fixed in 70%
ethanol. Immediately prior to the flow cytometry analysis, cells were stained with
freshly prepared propidium iodide solution containing RNase A for 30 min at
37°C, and 10,000 cells were analyzed for each sample on a FACSCalibur (Becton
Dickinson) flow cytometer. Cell cycle analysis was performed three times with
identical results.
Anchorage-independent growth was determined by using established tech-
niques. Briefly, 2,500 cells in 0.3% Noble agar were seeded in quadruplicate wells
of a 24-well plate, and the number of colonies was determined by direct counting
after 2 to 3 weeks. Rat C6 glioma cells were used as a positive control.
Cre-adenovirus and LacZ-adenovirus infection of primary cultured astro-
cytes. Primary astrocyte cultures were prepared from the brains of postnatal day
2 Nf1flox/flox mice as described above. Adenovirus type 5 (Ad5)-Cre and Ad5-
LacZ were purchased from the University of Iowa Gene Transfer Vector Core
(B. Davidson, Iowa City, Iowa). Briefly, Nf1flox/flox astrocytes at 75 to 80%
confluency were treated with Ad5-Cre or control Ad5-LacZ virus diluted in
growth medium containing 10% horse serum at a multiplicity of infection of 50
for 1 h at 37°C. After 1 h, the medium was removed, and the infected Nf1flox/flox
astrocytes were washed with PBS, pH 7.4, and then maintained in growth me-
dium with 10% horse serum for 4 days. We experimentally determined that 4
days represented the optimal time for complete Nf1 gene recombination and loss
of neurofibromin expression. After 4 days in culture, the Ad5-Cre- and Ad5-
LacZ-infected Nf1flox/flox astrocytes were collected for Western blotting or
proliferation assays, anchorage-independent growth experiments, or intracranial
implantation in immunocompromised (nu/nu) mice.
Intracranial implantation of astrocytes in nude mice. A total of 8  105 E12.5
Nf1/ and Nf1/ astroglial cells or Nf1/ astrocytes and Nf1/ astrocytes
generated by Ad5-Cre and Ad5-LacZ infection of Nf1flox/flox astrocytes were
resuspended in 10 l of growth medium and injected intracranially under aseptic
conditions into the brains of 6- to 8-week-old anesthetized athymic nu/nu mice by
using a stereotactic injection apparatus. The injection hole was filled with bone
wax, the skin was closed with staples, and injected mice were returned to their
cages for 8 to 12 weeks. Mice were euthanized, and their brains were removed for
processing and paraffin embedding.
Western blot analysis. Western blot analysis was performed on cultured as-
trocyte extracts prepared by homogenization in lysis buffer (20 mM Tris [pH 7.5],
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM glycerophosphate, 1 mM sodium orthovanadate, 1 ng of
leupeptin per ml). Protein concentrations were determined by using the BCA
protein assay (Pierce Chemical Company). Proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto Immobilon membranes (Millipore) for Western blotting. WA15a neurofi-
bromin (17) or NF1GRP-D (Santa Cruz Biotechnology Inc., Santa Cruz, Calif.)
(1:300 dilution) and tubulin antibodies (1:20,000 dilution; mouse monoclonal
DM1A; Sigma, St. Louis, Mo.) were used as primary antibodies. Secondary
antibodies were horseradish peroxidase-conjugated reagents (Sigma). Detection
was performed by using ECL chemiluminescence (Amersham).
RESULTS
Generation and characterization of GFAP-Cre transgenic
mice. To achieve astrocyte-specific Cre-mediated excision of
the Nf1 gene, we generated several lines of mice expressing Cre
recombinase under the control of the human GFAP promoter.
The 2.2-kb fragment of the human GFAP promoter (Gfa2)
was chosen based on previous work by Messing and Brenner
demonstrating astrocyte-specific expression in transgenic mice
(9). The IRES sequence was inserted to allow for cotranslation
of the nucleus-targeted Cre and -galactosidase (LacZ) pro-
teins from the same mRNA (Fig. 1A). In this fashion, LacZ
FIG. 1. Generation and characterization of GFAP-Cre transgenic mice. (A) Schematic diagram of the GFAP-Cre-IRES-LacZ transgene. The
transgene contains the 2.2-kb fragment of the human GFAP promoter (hGFAP) and cDNAs encoding the nucleus-targeted proteins Cre
recombinase (Cre) and -galactosidase (nLacZ). The IRES sequence allows cotranslation of the Cre and LacZ proteins from the same mRNA.
(B) Southern blot analysis of DNA from mouse tail biopsies digested with BglII and NotI to excise the GFAP-Cre-IRES-LacZ transgene (first five
lanes) and of the original GFAP-Cre-IRES-LacZ construct used for pronuclear injection (lane ) with a 1-kb Cre probe. Founder 8 carries an
8-kb transgene identical to the original construct (lane ). The GFAP-Cre transgenic mice showed strong LacZ expression in the brain (C), while
no LacZ expression was observed in the brain of wild-type littermates (D). Cre immunohistochemistry demonstrated Cre expression in the CA1
region of the hippocampus of the GFAP-Cre mice (E), whereas no Cre expression was detected in wild-type littermates (F). Double immuno-
fluorescence with anti--galactosidase antibodies (H; green) and anti-Cre antibodies (I; red) demonstrated colocalization of the Cre and LacZ
nuclear protein expression in the same cells in the CA1 region of the hippocampus (J; yellow). DAPI staining of nuclei is shown in panel G.
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reporter activity represents an indirect but reliable method for
detecting Cre expression patterns in vivo and facilitates the
identification of Nf1/ astrocytes.
We identified three founders by genotyping with Cre- and
LacZ-specific primers (lines 1, 6, and 8). Southern blotting of
tail DNA with a 32P-radiolabeled Cre probe verified the PCR
results (Fig. 1B). Founders were then crossed onto the
C57BL/6 background, and their offspring were evaluated for
-galactosidase activity in sections of several organs from
7-day-old transgenic pups. Robust LacZ expression was de-
tected in the brain (Fig. 1C) but not in other organs, including
heart, liver, kidney, and intestine (data not shown). No LacZ
expression was detected in wild-type littermates (Fig. 1D).
High levels of Cre expression were similarly detected in the
brains of GFAP-Cre transgenic mice (Fig. 1E), whereas no
expression was observed in control littermates (Fig. 1F). Dou-
ble immunofluorescence with anti--galactosidase and anti-
Cre antibodies showed that the Cre and LacZ expression co-
localized in the nuclei of the same cells in GFAP-Cre
transgenic mice (Fig. 1H, I, and J). There was neither LacZ nor
Cre immunofluorescence in brain sections from wild-type lit-
termates (not shown).
To evaluate the astrocyte specificity of LacZ expression in
these GFAP-Cre transgenic mice, we performed immunohis-
tochemistry by using antibodies that identify astrocytes, oligo-
dendrocytes, and neurons in combination with X-Gal staining.
LacZ expression was found in GFAP-positive astrocytes in
most regions of the brain, including hippocampus, corpus cal-
losum, and cerebellum, but not in MAP2-positive neurons or
APC-positive oligodendrocytes (Fig. 2). Similarly, no LacZ
expression was found in S-100-positive Schwann cells, associ-
ated with either large myelinated axons or small unmyelinated
axons, in the sciatic nerve (data not shown).
Two lines of transgenic mice were selected for further anal-
ysis (lines 1 and 8), and the results from one line (line 8) are
presented in this paper. Identical results were obtained with
line 1.
To determine when GFAP promoter-directed transgene ex-
pression was first detected in these lines, we performed a
developmental profile of -galactosidase activity during mouse
embryogenesis. -Galactosidase activity was first detected by
embryonic day 14.5 in both transgenic lines. By embryonic day
18.5, LacZ was robustly expressed in the brain, spinal cord, and
optic nerves of GFAP-Cre transgenic animals (Fig. 3).
To assess the function of the Cre transgene, GFAP-Cre mice
were crossed with the Z/AP reporter mouse strain (32). Effi-
cient Cre-mediated recombination resulted in loss of cytoplas-
mic -galactosidase activity and expression of the human al-
kaline phosphatase gene in astrocytes in the brain in vivo (A.
Guha, unpublished observations). Thus, these GFAP-Cre-
IRES-LacZ transgenic mice represent an efficient and specific
tool to delete conditional LoxP-interrupted genes specifically
in astrocytes in the mouse nervous system.
Nf1 astrocyte-specific knockout mice (Nf1GFAPCKO) do not
develop astrocytomas. To establish an astrocyte-specific Nf1
knockout mouse, we successively crossed GFAP-Cre-IRES-
LacZ mice with Nf1flox/flox mice. Nf1flox/flox mice have two
functional Nf1 alleles containing loxP sequences, as previously
reported (48). The Nf1flox allele behaves like a wild-type allele
despite the presence of an intronic neomycin resistance cas-
sette and loxP sequences. Nf1flox/flox mice have been breeding
for several years in our colony as well as in Parada’s laboratory
FIG. 2. -Galactosidase is expressed only in astrocytes in the brains of GFAP-Cre mice. LacZ is specifically expressed in GFAP-immunore-
active astrocytes (arrows point to representative astrocytes expressing LacZ) in the hippocampus, corpus callosum, and cerebellum. Note that
Bergmann glia in the cerebellum show high LacZ expression. APC-immunoreactive oligodendrocytes (stars) in the corpus callosum and MAP2-
immunoreactive neurons (arrowheads denote the neuronal cell bodies) in the hippocampus and cerebellum of the GFAP-Cre transgenic mice do
not demonstrate LacZ activity. Magnification, 400.
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FIG. 3. LacZ reporter expression during embryonic development of GFAP-Cre transgenic mice. -Galactosidase activity was detected by
embryonic day 14.5 in the brain of the GFAP-Cre transgenic mice. In E18.5 GFAP-Cre embryos, robust LacZ activity is detected in the brain,
spinal cord, and optic nerves. No LacZ expression is observed in a control littermate (E18.5 control). The intestines of both GFAP-Cre and control
mice show endogenous LacZ activity. Mouse embryos were photographed at 8 magnification at E11.5 and E13.5, 5 magnification at E15.5, and
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without evidence of neurological or brain anatomical abnor-
malities.
A cohort of 40 Nf1GFAPCKO mice and control littermates
(Nf1flox/flox and Nf1flox/wt mice) were monitored for 20
months for gross neurological abnormalities. These mice did
not show differences in size or weight compared to control
littermates and they were healthy and fertile. Hematoxylin and
eosin staining of their brains did not reveal any astrocytomas.
Analysis of serial coronal brain sections from 10- to 12-month-
old Nf1GFAPCKO mice (n  9) and control littermates (n  9)
did not identify any abnormalities suggestive of astrocytomas.
Finally, we were not able to detect any tumors by T1- and
T2-weighted magnetic resonance imaging by using a brain and
optic nerve protocol in 12-month-old Nf1GFAPCKO mice (n 
2) (S.-K. Song, data not shown).
Nf1GFAPCKO mice exhibit increased numbers of astrocytes
throughout the brain. Histological analysis of brain sections by
immunohistochemistry with the GFAP antibody revealed mod-
erate increases in astrocyte numbers throughout the brains of
Nf1GFAPCKO mice. In Fig. 4, whole brain sections, aligned
from rostral to caudal, showed higher GFAP staining in
Nf1GFAPCKO mice (right side of the panels, CKO) than brain
sections from control mice (left side of the panels, C). We did
not observe any reproducible regional differences in astrocyte
numbers, and the increased astrocytes appeared to be uni-
formly distributed throughout the brain. Higher magnification
identified increased numbers of astrocytes in several brain re-
gions, including the corpus callosum, cerebral cortex, and hip-
pocampus, of the conditional knockout mice (Fig. 4a to f).
To better analyze the morphology of the astrocytes, we also
performed GFAP and eosin staining of thin paraffin coronal
sections of the brains of adult Nf1GFAPCKO mice. Although we
observed a higher number of GFAP-immunoreactive astro-
cytes in the dentate gyrus as well as the CA1/CA2 and CA3
areas of the hippocampus in Nf1GFAPCKO mice than in their
control littermates, the morphology of the GFAP-positive as-
trocytes was similar between the mutant and the control mice
(Fig. 4g to l).
The number of astrocytes was determined by counting the
GFAP-immunoreactive cells (astrocytes) in the CA1 region of
the hippocampus of mutant mice and control mice. As shown
in Fig. 5A, 1.6-fold more astrocytes were present in the CA1
region of the hippocampus of 2-month-old Nf1GFAPCKO (n 
4) mice compared with control littermates (Nf1flox/flox [n  4]
and GFAP-Cre mice [n  4]). The number of astrocytes in the
CA1 region of the Nf1GFAPCKO mice increased slightly in
older mutant mice, rising to 1.8-fold at 6 months of age (n 3)
and 2.2-fold at 12 months (n  5) (Fig. 5B and C). The 6-
and 12-month-old control mice were either Nf1flox/flox or
Nf1flox/wt littermates.
To assess whether the increased number of GFAP-positive
astrocytes in the brain resulted from increased glial fibrillary
acidic protein expression, a property of reactive astrocytes, or
increased astrocyte proliferation, we performed double immu-
nofluorescence with anti-GFAP and anti-PCNA (proliferating
cell nuclear antigen) antibodies in coronal brain sections from
adult Nf1GFAP CKO mutant mice (n  3) and control mice (n
 3). There were increased numbers of PCNA-labeled cells in
the hippocampus (dentate gyrus as well as the CA1 and CA2/
CA3 regions) of Nf1GFAPCKO mice compared to control mice
(Fig. 6a), and 75% of the PCNA-positive (proliferating) cells
were GFAP immunoreactive and exhibited typical astrocyte
morphology, whereas 25% of the PCNA-labeled cells were
GFAP negative (Fig. 6c). We believe that these PCNA-labeled
cells represent astrocytes (GFAP positive) and astroglial pre-
cursor cells (GFAP negative) at different stages of develop-
ment. Since PCNA is a marker for proliferating cells, we con-
clude that the increased number of astrocytes observed in our
Nf1GFAPCKO mice reflects an increase in astrocyte prolifera-
tion.
Loss of Nf1 affects the growth but not the tumorigenic prop-
erties of Nf1GFAPCKO astrocytes in vitro. Analysis of primary
astrocyte cultures derived from Nf1 conditional knockout mice
demonstrated efficient Cre-mediated excision of the Nf1 gene
by PCR with primer sets that specifically recognize the recom-
bined Nf1 allele (R-Nf1). Whereas the PCR Nf1 recombina-
tion product was present in both GFAP-Cre Nf1flox/flox
(Nf1GFAPCKO) and GFAP-Cre Nf1flox/wt astrocytes, no re-
combination was detected in astrocyte cultures derived from
Nf1flox/flox littermates lacking Cre (Fig. 7A). As shown in Fig.
7B, neurofibromin expression was absent in astrocytes derived
from GFAP-Cre Nf1flox/flox (Nf1GFAPCKO) mice, and protein
levels were significantly decreased in GFAP-Cre Nf1flox/wt
astrocytes compared to Nf1flox/flox astrocytes lacking Cre, as
determined by Western blotting with a neurofibromin-specific
antibody. Tubulin was included as a control for protein load-
ing.
We have previously demonstrated that heterozygosity for
Nf1 confers a growth advantage for astrocytes in vitro and in
vivo (3, 18). To examine the role of neurofibromin in astrocyte
growth and tumor formation, we analyzed the growth and
tumorigenic properties of primary cultured astrocytes derived
from 2-day-old Nf1GFAPCKO and control Nf1flox/flox mice.
When astrocytes in culture at passage 1 were harvested and
counted, we observed a twofold growth advantage for
Nf1GFAPCKO compared with Nf1flox/flox astrocytes, as shown
in Fig. 7C. These results were also observed by [3H]thymidine
incorporation and flow cytometry analysis of the cellular DNA
content (data not shown). Although neurofibromin loss en-
hanced the growth properties of Nf1GFAPCKO astrocytes, Nf1
null astrocytes lacked tumorigenic properties. The astrocytes
derived from these Nf1 astrocyte-specific conditional knockout
mice did not grow in serum-free medium and were not able to
form colonies in soft agar (data not shown).
Nf1 inactivation influences the growth but not the tumori-
genic properties of embryonic or postnatal Nf1/ astroglial
cells. Our developmental study of -galactosidase activity in
the GFAP-Cre transgenic mice indicates that Cre-mediated
disruption of the Nf1 gene in astrocytes likely begins around
embryonic day 14.5. To eliminate the possibility that tumor
formation requires Nf1 inactivation at a different developmen-
tal time than embryonic day 14.5, we established embryonic
astroglial cultures from brains of conventional Nf1 knockout
mice (Nf1/) at embryonic day 12.5 and deleted the Nf1 gene
in astrocytes in vitro derived from postnatal day 2 Nf1flox/flox
mice by adenovirus-mediated Cre delivery.
Since conventional Nf1/ mice die in utero between em-
bryonic days 12.5 and 14 of a heart developmental defect
(double outlet right ventricle), we prepared primary astroglial
cultures from the brains of Nf1/ mice at embryonic day 12.5.
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Immunofluorescence analysis of Nf1/ astroglial cells in cul-
ture with anti-GFAP and antinestin antibodies, a marker for
undifferentiated neural cells, revealed that most of the cells in
culture (90%) were GFAP positive, while only a few of the
cells (10%) were nestin positive and GFAP negative. Nf1/
astroglial cells exhibited a slightly different morphology than
their Nf1/ and wild-type counterparts: they were smaller in
size, had a more elongated shape, and extended fewer pro-
cesses (data not shown). Western blotting of cellular extracts
from the cultured astroglial cells confirmed the loss of neuro-
FIG. 4. Astrocyte-specific Nf1 conditional knockout mice demonstrate moderate increases in astrocyte number. Low-power photomicrographs
of GFAP immunohistochemistry of 40-m brain sections (microtome) were aligned from rostral to caudal, with the right side of each panel
representing Nf1GFAPCKO brain sections (CKO) and the left side of each panel representing brain sections from control mice (C). Nf1GFAPCKO
mice demonstrate increased GFAP immunoreactivity throughout the brain. Higher magnification of the boxed areas in the brains of control mice
(C) on the left side of the upper panels (a, b, and c) and of the boxed areas in the brains of Nf1GFAPCKO mice (CKO) on the right side of the
upper panels (d, e, and f) revealed increased numbers of astrocytes in the corpus callosum, hippocampus, and cortex of Nf1GFAPCKO mice.
Increased numbers of astrocytes without major changes in morphology were also observed in Nf1GFAPCKO hippocampal sections by GFAP and
eosin staining (panels j, k, and l) compared to control mice (panels g, h, and i).
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fibromin in Nf1/ cells, whereas the Nf1/ cells had approx-
imately half of the amount of neurofibromin present in wild-
type astrocytes (Fig. 8A).
Nf1 null embryonic astrocytes demonstrated a fourfold in-
crease in growth compared to Nf1/ and a twofold increase in
growth compared to Nf1/ astrocytes (Fig. 8B). These results
were confirmed by [3H]thymidine incorporation (Fig. 8C) and
flow cytometry analysis of the cell cycle (Fig. 8D). In these
experiments, 77.5%, 9.6%, and 13.19% of the Nf1/ astroglial
cells were in G1, S, and G2/M, respectively, whereas 55.9%,
22.84%, and 22.07% of the Nf1/ astroglial cells were in G1,
S, and G2/M, respectively. However, Nf1
/ astroglial cells did
not grow in serum-free medium and did not form colonies in
soft agar (Fig. 8E). In addition, embryonic day 12.5 astroglial
Nf1/ cells were not able to induce astrocytoma formation
after intracranial implantation in the brains of immunocom-
promised, athymic (nu/nu) mice (data not shown; n  3).
To disrupt Nf1 at a later developmental time, we used high-
titer replication-defective adenoviruses containing Cre recom-
binase (Ad5-Cre) or -galactosidase (Ad5-LacZ) under the
control of the human cytomegalovirus promoter (41). Viral
delivery of Cre or LacZ (control) was achieved by infecting
astrocyte cultures derived from Nf1flox/flox cortex at postnatal
day 2 with Ad5-Cre and Ad5-LacZ (2). Complete Cre-medi-
ated recombination of the Nf1 gene was achieved at a multi-
plicity of infection of 50 and verified at the DNA level by PCR
analysis with specific primers (Fig. 9A) and at the protein
expression level by Western blotting (Fig. 9B).
Cre- and LacZ-adenovirus-infected Nf1flox/flox astrocyte
cultures (multiplicity of infection  50) were monitored for
their growth properties. The astrocytes infected with the Cre-
adenovirus exhibited a 1.7-fold growth advantage over the
LacZ-adenovirus-infected astrocytes after 5 days in culture
(Fig. 9C). In addition, loss of Nf1 expression at a later time in
the development of astrocytes did not confer any tumorigenic
properties on these astrocytes. Cre-infected Nf1flox/flox astro-
cytes did not grow in serum-free medium, did not form colo-
nies in soft agar, and were not able to induce astrocytomas
when injected in the brains of immunocompromised (nu/nu)
mice (n  3) (data not shown).
DISCUSSION
Previous studies have suggested that the Nf1 gene product,
neurofibromin, is an important growth regulator for astrocytes.
First, reduced Nf1 gene expression is associated with increased
astrocyte proliferation in vivo and in vitro (3, 18). This het-
erozygous growth advantage is cell autonomous and is associ-
ated with increased p21ras pathway activation, consistent with
the function of neurofibromin as a p21ras-GAP. Second, neu-
rofibromin expression increased during astrocyte growth arrest
under physiologic conditions in vitro (18, 21). Third, individu-
FIG. 5. The number of GFAP-immunoreactive astrocytes is increased in the hippocampus CA1 region of astrocyte-specific Nf1 conditional
knockout mice compared to that of control littermates. Quantitation of the GFAP-positive astrocytes in the CA1 region of the hippocampus of
the mutant and control mice demonstrated 1.6-fold more astrocytes in 2-month-old Nf1GFAPCKO mice than in GFAP-Cre and Nf1flox/flox controls
(A) and a slight increase to 1.8-fold in 6-month-old (B) and to 2.2-fold in 12-month-old (C) Nf1GFAPCKO mice compared with Nf1flox/flox and
Nf1flox/wt controls. Data are presented as mean values 	 SD and were analyzed by analysis of variance followed by the Bonferroni t test, with
significance set at P 
 0.05.
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als with NF1 develop astrocytomas at an increased frequency,
and loss of neurofibromin is observed in symptomatic NF1-
associated but not sporadic pilocytic astrocytomas (19, 25, 28,
30, 38). Collectively, these findings argue that NF1 inactivation
is associated with NF1 astrocytoma formation but do not ad-
dress the fundamental issue of whether neurofibromin loss is
necessary and sufficient for astrocytoma development. In an
effort to determine the contribution of neurofibromin to NF1
astrocytoma formation, we analyzed the effect of Nf1 inactiva-
tion in mouse astrocytes at various developmental times in
vitro and in vivo. Our results suggest that Nf1 loss provides a
clear growth advantage for astrocytes in vitro and in vivo but is
not sufficient for astrocytoma formation in mice.
Over the past few years, several transgenic lines of GFAP-
Cre mice have been developed that demonstrate Cre expres-
sion in astrocytes, but there is also considerable ectopic ex-
pression in several populations of neurons and a few other cell
types. By using the 2.2-kb fragment of either the mouse or
human GFAP promoter for the generation of Cre transgenic
mice, Cre expression was found primarily in astrocytes but also
in subpopulations of neurons in the hippocampus, dentate
gyrus, cortex, and cerebellum (33; K. Akassoglou and G. Ko-
lias, 1999, Cre transgenic database [http://www.mshri.on.ca
/nagy/Cre-being.htm]; A. Messing, 1997, Cre transgenic data-
base). The GFAP-Cre mice developed by Messing and cowork-
ers exhibit Cre expression in neural precursor cells as early as
embryonic day 10.5 (Zhu et al., unpublished data). Similar
results were also observed with other GFAP-Cre mice, in
which predominantly neuronal rather than astrocyte-specific
expression was detected (27).
In contrast, our GFAP-Cre transgenic lines demonstrated
robust astrocyte expression by embryonic day 14.5 but did not
have transgene expression in neurons, oligodendrocytes, or
Schwann cells. Based on these results, it is likely that our
Nf1GFAPCKO mice represent a good model of astrocyte-spe-
cific Nf1 inactivation in the central nervous system.
The lack of astrocyte tumor formation in these Nf1GFAPCKO
mice may reflect several possibilities. First, Nf1 inactivation
leads to tumor formation only if it occurs at the correct devel-
opmental time. To address this possibility, we analyzed the
effect of Nf1 loss at several developmental times, including
embryonic days 12.5 and 14.5 as well as postnatal day 2. This
was accomplished by preparing astrocyte cultures from con-
ventional Nf1/ mice at embryonic day 12.5 as well as post-
natal day 2 Nf1flox/flox cultures with Nf1 inactivation by Cre-
adenovirus in vitro. In addition, Nf1 inactivation occurred in
vivo by E14.5 in the Nf1GFAPCKO mice detailed in this report,
at a time that coincides with type I astrocyte differentiation,
and by E10.5 in the Nf1GFAPCKO mice generated by Parada
and associates (Zhu et al., unpublished data). Although these
FIG. 6. Increased astrocyte number in the brains of Nf1GFAPCKO mice is the result of increased astrocyte proliferation. PCNA immunofluo-
rescence identifies proliferating cells (red) in the CA1 region of the hippocampus of adult Nf1GFAPCKO (CKO) mice. White arrows point to
representative PCNA-labeled cells (panel a). Almost no PCNA-immunoreactive proliferating cells were present in the hippocampus of control
(C) mice (panel d). GFAP immunofluorescence (green) of astrocytes in the CA1 region of the hippocampus is shown for CKO mice (panel b) and
for control mice (panel e). Note that there are increased numbers of astrocytes in panel b, corresponding to the mutant mice, compared to panel
e (control mice). Merged PCNA/GFAP/DAPI images are shown for CKO (panel c) and control (panel f) mice. The nuclei of the cells in these
images are stained with DAPI and appear dark blue. The white arrows in the merged PCNA/GFAP/DAPI (panel c) for the Nf1GFAPCKO mice
denote several double-labeled GFAP-positive astrocytes with PCNA-labeled nuclei (pink). No GFAP/PCNA/DAPI-immunolabeled cells are
observed in the hippocampus of control mice (panel f).
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three different Nf1-deficient astrocyte populations exhibited
defects in their growth properties, they lacked tumorigenic
properties and could not induce astrocytoma formation when
implanted intracranially in the brains of immunocompromised
mice.
During development, neurofibromin expression in rodent
embryos is first detected uniformly in all tissues by day 10,
including neuroglial precursor populations (22, 35). During
embryonic development and in the adult, neurofibromin ex-
pression in the nervous system is highest in neurons with com-
paratively very low levels of expression in astrocytes. Studies
are under way to investigate the relationship between neuro-
fibromin expression and astroglial cell differentiation.
Second, p21ras activation may not provide sufficient mito-
genic signaling for astrocyte transformation. This possibility
was evaluated in our previous studies, in which transgenic mice
that express an oncogenic p21ras (RASG12V) molecule specif-
ically in astrocytes (B8 RAS transgenic mice) were generated.
These B8 mice demonstrated massive astrocyte proliferation
throughout the brain and developed high-grade astrocytomas
around 3 to 4 months of age (13). Analysis of these tumors
demonstrated a number of secondary “cooperating” genetic
changes previously reported in human high-grade astrocyto-
mas, including loss of p16, p53, and PTEN/MMAC1 as well as
increased expression of CDK4 and the epidermal growth fac-
tor receptor. The reason that the B8 RAS transgenic mice
develop high-grade astrocytomas while Nf1GFAPCKO mice do
not likely reflects the fact that we overexpressed a constitu-
tively activated p21ras molecule at high levels sufficient to ini-
tiate transformation, which may have resulted in secondary
genetic changes. This high, nonphysiological level of p21ras
activation was not achieved in the Nf1GFAPCKO mice.
Third, it is possible that additional genetic events in combi-
nation with Nf1 inactivation might be required for NF1-asso-
ciated astroglial tumorigenesis. Previous work by Jacks and
colleagues has shown that combined Nf1 and p53 loss can lead
to the formation of high-grade malignant astrocytomas (39).
Since individuals with NF1 develop low-grade astrocytomas,
and not high-grade malignant gliomas, it is unlikely that p53
loss is the critical genetic event in NF1-associated astrocytoma
formation. In this regard, p53 mutations are not typically de-
tected in NF1-associated or sporadic pilocytic astrocytomas
(23, 30). Recent studies from our laboratory with gene expres-
sion profiling of NF1-associated pilocytic astrocytomas have
demonstrated significant alterations in the expression of genes
involved in cell adhesion, motility, and actin cytoskeleton-as-
FIG. 7. Inactivation of Nf1 influences the growth but not the tumorigenic properties of astrocytes derived from Nf1GFAPCKO mice in vitro.
(A) Cultured astrocytes were tested by PCR with specific primers to detect the presence of the Cre transgene, the conditional Nf1flox allele, and
the recombined Nf1 allele. The recombined Nf1 allele (R-Nf1), as a result of Cre-mediated recombination of the conditional allele (floxNf1), is
detected only in astrocytes that contain the Cre transgene (lanes 1 and 2) derived from astrocyte-specific Nf1 knockout mice. (B) Neurofibromin
protein expression is lost in astrocytes in culture derived from the brains of GFAP-Cre Nf1flox/flox (Nf1GFAPCKO) mice and reduced in astrocytes
derived from GFAP-Cre Nf1flox/wt mice compared with astrocytes from the Nf1flox/flox littermates. (C) Cultured astrocytes derived from
Nf1GFAPCKO mice (Nf1CKO) show a growth advantage in comparison with control Nf1flox/flox (Nf1flox) astrocytes.
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sociated processes (20). These changes are not seen in Nf1/
astrocytes and may reflect some of the additional genetic
changes associated with NF1 astrocytoma tumorigenesis. Fur-
ther work will be necessary to determine whether these
changes in combination with NF1 inactivation are necessary
and sufficient for NF1-associated astrocytoma formation or
whether they merely represent gene expression changes asso-
ciated with NF1 astrocytoma development.
Fourth, conventional models of astrocytomas employ the
GFAP promoter, which drives expression of transgenes in
GFAP-immunoreactive type 1 fibrillary astrocytes. It is con-
ceivable that NF1-associated low-grade (pilocytic) astrocyto-
mas do not arise from type 1 fibrillary astrocytes, but rather
from a different cell of origin. Several studies have highlighted
the inherent differences between pilocytic astrocytomas and
high-grade fibrillary astrocytomas, with regard to both genetic
changes and glial cell protein expression patterns (11, 30, 40,
44, 47). For instance, pilocytic astrocytomas express the unique
PEN5 epitope shared with cells and tumors of an oligodendro-
cyte lineage (15). This marker is not expressed in fibrillary
astrocytes or astrocytomas. Recent studies from our laboratory
have demonstrated expression of oligodendrocyte-associated
transcripts, such as PLP, PMP-22, MBP, and oligodendrocyte
myelin glycoprotein in pilocytic astrocytomas, suggesting that
these NF1-associated tumors exhibit some gene expression
features of oligodendrocyte type 2 astrocyte cells (20). In this
regard, it may be necessary to inactivate Nf1 in the correct
progenitor cell, perhaps an oligodendrocyte type 2 astrocyte or
glial restricted precursor cell, in order to generate NF1-asso-
ciated astrocytomas in mice.
Fifth, it is possible that NF1-associated astrocytoma forma-
tion requires a permissive brain environment. In children with
NF1, grade I astrocytomas are most frequently found in the
optic pathway (31). It is possible that Nf1 inactivation in spe-
cific populations of astrocytes in the brain is required. In this
regard, astrocytes from different regions of the brain may have
different functional properties. Astrocytes from different re-
gions of the brain have been reported to have different re-
sponses to agents that elevate cyclic AMP, regional specificity
in gap junction coupling (29), differences in glutamate and
serotonin uptake (1), and distinctive growth patterns (14). A
more detailed analysis of the eyes and optic nerves of
Nf1GFAPCKO mice is presently under way.
Similarly, NF1-associated astrocytomas form in the brains of
children in which the surrounding cellular milieu is heterozy-
gous for a germ line NF1 mutation. It is possible that NF1
FIG. 8. Embryonic day 12.5 Nf1/ astroglial cells show a significant increase in growth in vitro but lack tumorigenic properties. (A) Western
blotting of astroglial cell extracts with an antineurofibromin antibody demonstrated loss of neurofibromin in Nf1/ astroglial cells. (B) Growth
curves of Nf1/, Nf1/, and Nf1/ astrocytes showed a significant growth advantage for Nf1/ astroglial cells at 3 and 6 days in culture.
(C) When stimulated with fetal bovine serum, Nf1/ astroglial cells showed increased [3H]thymidine incorporation in comparison with Nf1/
astrocytes. (D) The growth advantage observed by cell counting and [3H]thymidine incorporation was also demonstrated by flow cytometry analysis
of the cell cycle of Nf1/ and Nf1/ cells. (E) Nf1/ and Nf1/ astroglial cells do not form colonies in soft agar. C6 glioma cells were used
as a positive control in the soft agar assay.
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astrocytoma formation requires that the brain environment
contain Nf1/ cells. To address the possibility that astrocy-
toma formation in Nf1GFAPCKO mice might require an Nf1/
brain environment, we are in the process of generating GFAP-
Cre Nf1flox/mut mice, in which the brain is Nf1/ but the
astrocytes are Nf1/. In addition, experiments are under way
to examine the effect of intracranial implantation of Nf1/
astrocytes into the brains of Nf1/ mice on astrocytoma for-
mation. To date, Nf1/ mice in which Nf1-deficient astrocytes
have been intracranially implanted are healthy and asymptom-
atic after 6 months (L. Fink, Y. L. Wu, and D. H. Gutmann,
unpublished observations).
In summary, our studies emphasize that neurofibromin is an
important growth regulator for astrocytes but that astrocytoma
formation may require more complex interactions involving
cooperating genetic events and a permissive brain environ-
ment. Further work on the relationship between neurofibro-
min function, astrocyte growth regulation, and pilocytic astro-
cytoma formation should yield critical insights into the
molecular pathogenesis of NF1-associated astrocytomas and
result in the development of essential preclinical mouse mod-
els for specific features of the human disease.
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